Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2022-003016-87-HU
EUCTR2022-003016-87-HUActive, not recruitingPhase 1

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDYTO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OFPONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATEDCONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABELTREATMENT PERIOD

Pfizer Inc.0 sites168 target enrollmentStarted: December 14, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
168
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Participants aged =18 years (or the minimum age of consent if >18 in accordance with local regulations) at Screening who have signed informed consent.
  • •a. A female participant is eligible to participate if she is not pregnant or
  • •breastfeeding.
  • •b. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.
  • •Disease Characteristics:
  • •2. Documented histologic or cytologic diagnosis of NSCLC, PANC, or CRC receiving standard of care (which may include systemic therapy).
  • •3. Cachexia defined by Fearon criteria of weight loss as (See Section 8.1.1 for details if the participant’s body weight is unavailable from medical record):
  • •- BMI <20 kg/m2 with involuntary weight loss of >2% within 6 months prior to
  • •- involuntary weight loss of >5% within 6 months prior to screening irrespective of BMI.
  • •4. Serum GDF-15 concentrations of =1.5 ng/mL (as measured using the Investigational Use Only Roche Elecsys GDF 15 assay)10 at Screening.
  • •5. Participants who are assessed by the investigator to be able to participate for Part A with ECOG PS =3.
  • •Other Inclusion Criteria:
  • •6. Participants who are willing and able to comply with all scheduled visits, treatment
  • •plan, laboratory tests, lifestyle considerations, and other study procedures.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 67
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 101

Exclusion Criteria

  • •Medical Conditions:
  • •1. Current active reversible causes of decreased food intake, as determined by the Investigator. These causes may include, but are not limited to:
  • •- NCI CTCAE Grade 3 or 4 oral mucositis;
  • •- NCI CTCAE Grade 3 or 4 GI disorders (nausea, vomiting, diarrhea, and
  • •constipation);
  • •- Mechanical obstructions making patient unable to eat.
  • •2. Receiving tube feedings or parenteral nutrition (either total or partial) at the time of Screening or Randomization.
  • •3. Cachexia caused by other reasons, as determined by the investigator, including, but not limited to:
  • •- Severe COPD requiring use of home O2;
  • •- NYHA class III-IV heart failure;
  • •4. Undergoing major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization. Patient must be well recovered from acute effects of surgery prior to Screening. Patient should not have plans to undergo major surgical procedures during the study.
  • •5. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study.
  • •6. History of allergic or anaphylactic reaction to any therapeutic or diagnostic
  • •monoclonal antibody (IgG protein) or molecules made of components of monoclonal antibody.
  • •Prior/Concurrent Therapy:
  • •7. Initiation of new treatment with systemic glucocorticoids within the 4 weeks prior to the first dose of study intervention through Week 16; stable (ie, no significant change to dosage or frequency of administration in prior 4 weeks) steroid therapy eg, dexamethasone as part of pre-medication or daily oral prednisone is permissible. Refer to Section 6.9 and Appendix 10.
  • •8. Concurrent administration with anamorelin hydrochloride (eg, within 30 days prior to the first dose of study intervention through Week 16). Refer to Section 6.9 and Appendix 10.
  • •Prior/Concurrent Clinical Study Experience:
  • •9. Concurrent investigational products (including drug, biologic agents, or vaccines) are not permitted within 30 days (or as determined by the local requirement) or 5 half-lives (whichever is longer) of the first dose of study intervention through the duration of the study (including both Part A and B). Refer to Section 6.9 and Appendix 10.
  • •10. Enrollment in a previous study with ponsegromab.
  • •Diagnostic Assessments:
  • •11. History of severe liver disease or cirrhosis, unrelated to metastatic cancer. Potential study participants with the following liver function test abnormalities will also be excluded:
  • •- Total bilirubin =1.5 × ULN (except for Gilbert’s syndrome)
  • •- AST >3 × ULN (AST > 5X ULN if there is liver involvement by the tumor)
  • •- ALT >3 × ULN (ALT >5X ULN if there is liver involvement by the tumor)
  • •- Alkaline phosphatase >3 x ULN (Alkaline phosphatase >5X ULN in case of bone metastases).
  • •12. Renal disease requiring dialysis or eGFR<30 mL/min/1.73m2 calculated using 2021 CKD-EPI Equations described in Appendix 7.
  • •Other Exclusion Criteria:
  • •13. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Investigators

Similar Trials

Active, not recruiting
Phase 1
A clinical trial to evaluate whether a potential new drug is an effective and safe way to make damaged kidneys work better in patients with type II diabetes
EUCTR2010-021358-20-GBPfizer Inc. 235 east 42nd Street, New York, NY 10017256
Active, not recruiting
Phase 1
A clinical study to evaluate the effects and safety of three doses of Tofacitinib (a drug that is being investigated for the treatment of rheumatoid arthritis) in subjects with active Ankylosing spondylitis (AS) (a form of Arthritis)Ankylosing Spondylitis (AS)MedDRA version: 17.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2011-005689-39-SKPfizer Inc. 235 East 42nd Street, New York, 10017208
Active, not recruiting
Phase 1
Evaluation of EDP-938 in subjects aged 28 days to 36 months infected with respiratory syncytial virus (RSV)
EUCTR2020-001966-13-PLEnanta Pharmaceuticals, Inc.90
Active, not recruiting
Phase 1
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS
EUCTR2018-004431-79-GBCelgene Corporation300
Active, not recruiting
Phase 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12-WEEK ADMINISTRATION OF PF-00734200 TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON METFORMIN TREATMENTPATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON METFORMIN TREATMENTMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitus
EUCTR2007-007588-26-PLPfizer Inc., 235 East 42nd Street, New York, NY 10017225